UK-based 30 Technology sold part of its nitric-oxide-based antimicrobial technology portfolio to Convatec in a deal worth up to £176m (approximately $220m).
The initial value of the acquisition is £45m, however further contingent payments of up to £131m will be awarded to 30 Health dependent on the achievement of “specific regulatory approvals...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?